DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. The company’s initial focus is on glioblastoma, a devastating brain tumor that is resistant to conventional therapies. DNAtrix’s lead product, DNX-2401, is a modified common cold virus that targets and kills cancer cells selectively. DNX-2401 is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date. DNAtrix is also working to expand its platform technology for treating other cancers, with high unmet medical need. The company’s pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient’s immune system to trigger an aggressive anti-tumor T-cell response.